FIGURE 6.

miRisten treatment blocks leukemia transformation in a murine MDS model. (A) After a serial transplant, we have set up a cohort of tertiary transplant animals. Then we treated the transplants with SCR, miRisten (10 mg/kg/day), DAC (0.5 mg/kg, 3 times/week), or a combination of miRisten and DAC for 3 weeks (n = 5‐6 per group) after robust engraftment, BM, PB, and SP were harvested and analyzed, then BM cells in each group were transplanted into next CD45.1 recipients (quaternary transplants) to monitor leukemia transformation. (B‐D) WBC counts (B), BM smears (red arrows, blasts; blue arrow, dysplasia cells) (C), and survival curves (D) derived from quaternary transplant mice that received BM cells from donors that had undergone indicated treatments. Results shown represent mean ± SEM. ***P < 0.001,****P < 0.0001; NS: not significant; by two‐tailed, paired Student's t‐test. The log‐rank test was used to assess significant differences between survival curves